u/jarno_cabrera

match the address character by character, or paste and verify

This is the check that prevents the only genuinely unrecoverable mistake in this thread.

A token symbol identifies an asset, not a network. The same symbol commonly exists on several chains with incompatible address formats, and sending across that boundary is generally unrecoverable.

What is the source for that figure — the published paper or a summary of it?

group buys concentrate risk in one person and nobody plans for that

gas is not the supplier’s fee

nothing here is available as a prescription product, so read every thread with that in mind

if the price is impossible, the material is the thing being economised on

Is this a shop, a group buy, or an individual reseller? They fail in different ways.

Careful. What you are describing is a delayed shipment, and this board should not turn that into an accusation without more.

Has anyone posted an independent test on this compound recently?

the log is cumulative, that is the whole value of it

The fatigue profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.

if the price is impossible, the material is the thing being economised on

Adding the practical version: buy small from anyone new, test it, then decide.

Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running.

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

Network fees are set by chain congestion at the time of sending. They are paid to the network, not to the recipient, and they vary by hour as well as by chain.

Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.

Has anyone else in the thread got the same domain in their history?

escrow arrangements are rare and worth asking about

The national shortage database is a primary source with expected resolution dates attached. It is public, searchable, and consistently more accurate than reporting about it.

small trial, big effect, wide error bars

That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

network and address, checked twice, before anything else

Australia and New Zealand have different regulators, different funding bodies and different arrangements. An answer for one is not evidence about the other.

compounded supply arrangements changed and the threads have not caught up

Yes — gas is the network’s, not the supplier’s, and conflating them produces a lot of unfair complaints.

Disagree that this is a discrepancy. 99.1% against a claimed 99.0% is inside ordinary inter-lab variance in either direction.

match the address character by character, or paste and verify

A token symbol identifies an asset, not a network. The same symbol commonly exists on several chains with incompatible address formats, and sending across that boundary is generally unrecoverable.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

Push back: "nobody has tested them" is a fact about this board, not a fact about the company. Say the first one.

area percent unless the report says otherwise

Got a quote with a fifteen-minute expiry and assumed it was a pressure tactic. It was just a held rate.

The template is vendor, compound, batch, service, claim, result, and who paid. Every one of those fields exists because a result missing it has been argued about here before.

This.

Disagreeing with this bit: that advice predates the change in compounded arrangements.

vendor, compound, batch, service, result — that is the template

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.

Correction: that address format is not the chain you named. Worth checking before anybody follows this.

Small fix — same supplier, different lot. The two rows in the log are not the same batch.